Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
98 Cards in this Set
- Front
- Back
tidal volume VT or TV
|
-volume of air inhaled and exhaled w each breath
|
|
tidal volume VT or TV normal values
|
500ml or 5-10ml/kg
|
|
tidal volume VT or TV significance
|
TV may not vary, even w severe disease
|
|
Inspiratory reserve volume IRV
|
-maximum volume of air that can be inhaled after a normal inhalation
|
|
Inspiratory reserve volume IRV normal values
|
3000ml
|
|
Expiratory reserve volume ERV
|
the maximum volume of air that can be exhaled forcibly after a normal exhalation
|
|
Expiratory reserve volume ERV normal values
|
1100ml
|
|
Expiratory reserve volume ERV significance
|
ERV is decreased with restrictive conditions such as obesity, ascities, pregnancy
|
|
Residual volume RV
|
the volume of air remaining in the lungs after a maximum exhalation
|
|
Residual volume RV normal values
|
1200ml
|
|
Residual volume RV significance
|
RV may be increased with obstructive disease
|
|
Vital capacity VC
|
the maximum volume of air exhaled from the point of maximum inspiration
VC= TV + IRV + ERV |
|
Vital capacity VC normal values
|
4600ml
|
|
Vital capacity VC significance
|
a decrease in VC may be found in neuromuscular disease, generalized fatigue, atelectasis, pulmonary edema, COPD, and obesity
|
|
Inspiratory capacity IC
|
the maximum volume of air inhaled after normal expiration
IC= TV + IRV |
|
Inspiratory capacity IC normal values
|
3500ml
|
|
Inspiratory capacity IC significance
|
a decrease in IC may indicate restrictive disease. may also be decreased w obesity
|
|
Functional residual capacity FRC
|
the volume of air remaining in the lungs after a normal expiration
FRC= ERV + RV |
|
Functional residual capacity FRC normal values
|
2300ml
|
|
Functional residual capacity FRC significance
|
FRC may be increased w COPD and decreased w ARDS and obesity
|
|
total lung capacity TLC
|
the volume of air in the lungs after a maximum inspiration
TLC= TV + IRV + ERV + RV |
|
total lung capacity TLC normal values
|
5800ml
|
|
total lung capacity TLC significance
|
TLC may be decreased w restrictive disease (atelectasis, pneumonia) and increased in COPD
|
|
Eupnea
|
normal breathing at 12-18 breaths/min
|
|
Bradypnea
|
slower than normal rate (<10 breaths/min), w normal depth & regular rhythm
-associated w increased intracranial pressure, brain injury, and drug OD |
|
Tachypnea
|
rapid, shallow breathing > 24 breaths/min
-associated w pneumonia, pulm edema, metabolic acidosis, septicemia, severe pain, or rib fracture |
|
Hypoventilation
|
shallow, irregular breathing
|
|
Hyperpnea
|
increase depth of respirations
|
|
hyperventilation
|
increased rate and depth of breathing that results in decreased PaCO2 level
-inspiration and expiration are nearly = in duration -called kussmaul's respiration if associated w diabetic ketoacidosis or renal origin |
|
apnea
|
period of cessation of breathing; time duration varies; life threatening if sustained
|
|
Cheyne-stokes
|
-regular cycle where the rate & depth of breathing increase, then decrease until apnea (usually about 20sec) occurs
-duration of apnea may vary and progressively lengthen; therefore is timed & recorded -associated w heart failure & damage to the respiratory center (drug induced, tumor, or trauma) |
|
Biot's respiration
|
-periods of normal breathing (3-4breaths) followed by varying period of apnea (usually 10-60sec)
-aka clustered breathing -associated w some nervous system disorders |
|
flatness percussion ex.
|
intensity-soft
pitch-high duration-short location-thigh ex. large pleural effusion |
|
dullness percussion ex.
|
intensity-medium
pitch-medium duration-medium location-liver ex. lobar pneumonia |
|
resonance percussion ex.
|
intensity-loud
pitch-low duration-long location-normal lung ex. simple chronic bronchitis |
|
hyperresonance percussion ex.
|
intensity-very loud
pitch-lower duration-longer location-none normally ex. emphysema, pneumothorax |
|
tympany percussion ex.
|
intensity-loud
pitch-high location ex. gastric air bubble or puffed out cheek |
|
vesicular
|
-inspiratory sounds longer than expiratory
soft, low -entire lung field except over the upper sternum & between the scapulae |
|
bronchiovesicular
|
-inspiratory = expiratory (about)
intermediate intensity & pitch -often in the 1st & 2nd interspaces anteriorly and between the scapulae (over the main bronchus) |
|
bronchial
|
-expiratory sounds longer than inspiratory
loud, high pitch -over manubrium, if heard at all |
|
tracheal
|
-inspiratory & expiratory sounds about =
loud, high pitched -over trachea in the neck |
|
crackles in general
|
soft, high pitched, discontinuous popping sounds
-may or may not be cleared by coughing |
|
crackles in general-etiology
|
secondary to fluid in the airways or alveoli or to delayed opening of collapsed alveoli
-associated with heart failure & pulmonary fibrosis |
|
coarse crackles
|
discontinuous popping sounds heard in early inspiration; harsh, moist sound originating in the large bronchi
|
|
coarse crackles-etiology
|
associated w obstructive pulmonary disease
|
|
fine crackles
|
discontinuous popping sounds heard in late inspiration
-sounds like hair rubbing together; originates in alveoli |
|
fine crackles-etiology
|
associated w intersitial pneumonia, restrictive pulm disease (ex. fibrosis)
-in early inspiration are associated w bronchitis or pneumonia |
|
wheezes in general
|
usually heard on expiration-but can be on inspiration
|
|
wheezes in general-etiology
|
associated w bronchial wall oscillation & changes in airway diameter
-associated w chronic bronchitis or bronchiectasis |
|
sonorous wheezes (rhonchi)
|
deep, low pitched rumbling sounds heard primarily during expiration
-caused by air moving through narrowed tracheobronchial passages |
|
sonorous wheezes (rhonchi)-etiology
|
associated w secretions or tumor
|
|
sibilant wheezes
|
continuous, musical, high pitch, whistle like sounds heard during insp & exp
-caused by air passing through narrowed or partially obstructed airways -may clear w coughing |
|
sibilant wheezes-etiology
|
associated w bronchospasm, asthma, & build up of secretions
|
|
pleural friction rub
|
harsh crackling sound (imitated by rubbing thumb & finger tog near ear)
-may subside pt holds breath-coughing will not clear -best heard over lower lateral anterior surface of thorax -sound enhanced by applying pressure to the chest wall w diaphragm of stethoscope |
|
pleural friction rub-etiology
|
secondary to inflammation & loss of lubricating pleural fluid
|
|
consolidation (ex. pneumonia)
|
tf increased
percussion dull bronchial breath sounds, crackles, bronchophony, egophony, whispered pectoriloquy |
|
bronchitis
|
tf normal
percussion resonant normal to decreased breath sounds, wheezes |
|
emphysema
|
tf decreased
percussion hyperresonant decreased intensity of breath sounds, usually w prolonged expiration |
|
asthma (severe attack)
|
tf normal to decreased
percussion resonant to hyperresonant wheezes |
|
pulmonary edema
|
tf normal
percussion resonant crackles at lung base, possibly wheezes |
|
pleural effusion
|
tf absent
percussion dull to flat decreased to absent breath sounds, bronchial breath sounds & bronchophony, egophony, & whispered pectoriloquy above the effusion over the area of compressed lung |
|
pneumothorax
|
tf decreased
percussion hyperresonant absent breath sounds |
|
atelectasis
|
tf absent
percussion flat decreased to absent breath sounds |
|
forced vital capacity FVC
|
VC performed w a maximally forced expiratory effort
|
|
forced vital capacity FVC remarks
|
often reduced in COPD bc of air trapping
|
|
forced expiratory volume FEVt (usually FEV1)
|
volume of air exhaled in the specific time during the performance of forced vital capacity
FEV1 is volume exhaled in 1sec |
|
forced expiratory volume FEVT (usually FEV1) remarks
|
a valuable clue to the severity of the expiratory airway obstruction
|
|
ratio of timed forced expiratory volume to forced vital capacity
FEVt/FVC% (usually FEV1/FVC%) |
FEVt expressed as a % of the FVC
|
|
ratio of timed forced expiratory volume to forced vital capacity
FEVt/FVC% (usually FEV1/FVC%) remarks |
another way of expressing the presence or absence or airway obstruction
|
|
forced expiratory flow
FEF200-1200 |
mean forced expiratory flow between 200 and 1200ml of the FVC
|
|
forced expiratory flow
FEF200-1200 remarks |
an indicator of large airway obstruction
|
|
forced midexpiratory flow FEF25-75%
|
mean forced expiratory flow during the middle half of the FVC
|
|
forced midexpiratory flow FEF25-75% remarks
|
slowed in small airway obstruction
|
|
forced end expiratory FEF75-85%
|
mean forced expiratory flow during the terminal portion of the FVC
|
|
forced end expiratory FEF75-85% remarks
|
slowed in obstruction of smallest airways
|
|
maximal voluntary ventilation MVV
|
volume of air expired in a specific period (12sec) during repetitive maximal effort
|
|
maximal voluntary ventilation MVV remarks
|
an important factor in exercise tolerance
|
|
common types of bronchodilator meds for COPD
|
.
|
|
salbutamol, albuterol (Proventil, Ventolin)
|
Beta2-Adrenergic Agonist Agents
|
|
fenoterol (Alupent, Isuprel)
|
Beta2-Adrenergic Agonist Agents
|
|
terbutaline (Brethine)
|
Beta2-Adrenergic Agonist Agents
|
|
formoterol (Foradil)
|
Beta2-Adrenergic Agonist Agents
|
|
salmeterol (Serevent, Diskus)
|
Beta2-Adrenergic Agonist Agents
|
|
salbutamol, albuterol (Proventil, Ventolin)
routes & duration |
inhaler, nebulizer, oral
short duration of action |
|
fenoterol (Alupent, Isuprel)
routes & duration |
inhaler, nebulizer, oral
short duration of action |
|
terbutaline (Brethine)
routes & duration |
inhaler
short duration of action |
|
formoterol (Foradil)
routes & duration |
inhaler
long duration of action |
|
salmeterol (Serevent, Diskus)
routes & duration |
inhaler
long duration of action |
|
Ipratropium bromide (Atrovent)
|
Anticholinergic Agents
|
|
Ipratropium bromide (Atrovent)
routes & duration |
inhaler, nebulizer
short duration of action |
|
fenoterol/ipratropium (Duovent)
|
Combination Short-Acting Beta-2 Adrenergic Agonist and Anticholinergic Agents
|
|
salbutamol/ipratropium (Combivent)
|
Combination Short-Acting Beta-2 Adrenergic Agonist and Anticholinergic Agents
|
|
fenoterol/ipratropium (Duovent)
routes & duration |
inhaler, nebulizer
short |
|
salbutamol/ipratropium (Combivent)
routes & duration |
inhaler, nebulizer
short |
|
aminophylline (Phyllocontin, Truphylline)
|
Methylxanthines
|
|
theophylline (Theo-Dur, Slo-Bid)
|
Methylxanthines
|
|
aminophylline (Phyllocontin, Truphylline)
routes & duration |
oral
variable duration |
|
theophylline (Theo-Dur, Slo-Bid)
routes & duration |
oral
variable duration |